| Literature DB >> 29238165 |
Galal Elgemeie1, Farag Altalbawy2,3, Mohammed Alfaidi3, Rania Azab2,4, Atef Hassan5.
Abstract
The present research describes the synthesis of novel 5-benzoyl-N-substituted-amino- and 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones 5a-c and 6a-c via the reaction ofEntities:
Keywords: 2-benzoyl-3,3-bis(alkylthio)acrylonitriles; 5-benzoyl-N-substituted-amino-4-alkylsulfanyl-2 pyridones; 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones; N-cyanoacetohydrazide; amino-2-pyridones; antimicrobial activity; cyanoaceto-N-phenylsulfonylhydrazide
Mesh:
Substances:
Year: 2017 PMID: 29238165 PMCID: PMC5713685 DOI: 10.2147/DDDT.S149615
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Scheme 1Synthesis of 1,6-diamino-5-benzoyl-4-(alkylthio)-2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives 5a–c and N-[6-amino-5-benzoyl-3-cyano-4-(alkylthio)-2-oxopyridin-1(2H)-yl]benzene-sulfonamide derivatives 6a–c and 4,5-diamino-6-oxo-3-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carbonitrile (7).
Scheme 2Synthesis of 8-benzoyl-2-(aryl)-7-(alkylthio)-5-oxo-3,5-dihydro[1,2,4]triazole-[1,5-a]pyridine-6-carbonitrile (12–14)a–c and 2-(aryl)-5-oxo-9-phenyl-5,7-dihydro-3H-pyrazolo[4,3-c][1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile 15a–c.
Antibacterial and antifungal activity of synthesized compounds 5a–c, 6a–c, 7, 12a–c, and 15a–c against Staphylococcus aureus (SA), Escherichia coli (EC), and Candida albicans (CA) isolates using well diffusion test
| Compound | Zone-area inhibition (mm) of synthesized compounds at gradual concentration (mg/mL) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1
| 2
| 3
| 4
| 5
| |||||||||||
| SA | EC | CA | SA | EC | CA | SA | EC | CA | SA | EC | CA | SA | EC | CA | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 10 | 0 | 0 | 12 | 0 | 0 | 14 | 10 | 0 | 25 | 12 | 11 | 30 | |
| 0 | 0 | 10 | 0 | 0 | 15 | 0 | 0 | 20 | 11 | 10 | 20 | 12 | 12 | 22 | |
| 0 | 0 | 10 | 0 | 0 | 15 | 0 | 10 | 18 | 10 | 15 | 22 | 12 | 18 | 25 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 15 | 0 | 0 | 20 | 0 | 0 | 22 | 0 | 10 | 24 | 0 | 13 | 25 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 11 | 10 | 12 | 15 | 13 | |
| 0 | 0 | 20 | 0 | 0 | 20 | 0 | 0 | 25 | 10 | 12 | 30 | 10 | 15 | 35 | |
Notes:
For the control antifungal (fluconazole 20 μg), the zone of inhibition was 15 mm, and for the control antibacterial (levofloxacin 3.25 μg), the zone of inhibition was 18 mm. ATCC designations for EC, SA, and CA 11775, 12600, and 26555, respectively.
Transmittance and turbidity of treated Staphylococcus aureus and Escherichia coli with the synthesized compounds 5a–c, 6a–c, 7, 12a–c, and 15a–c
| Compound | Transmittance of treated microbial cells | |||||||
|---|---|---|---|---|---|---|---|---|
| 4 mg/mL
| 5 mg/mL
| 4 mg/mL
| 5 mg/mL
| |||||
| T% (clearance) | Degree of turbidity | T% (clearance) | Degree of turbidity | T% (clearance) | Degree of turbidity | T% (clearance) | Degree of turbidity | |
| Untreated | 2 | ++++ | 2 | ++++ | 2 | ++++ | 2 | ++++ |
| 95 | + | 97 | − | 5 | ++++ | 95 | + | |
| 95 | + | 97 | − | 93 | ++ | 100 | − | |
| 95 | + | 97 | − | 100 | − | 100 | − | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 0 | ++++ | 0 | ++++ | |
| 0 | ++++ | 0 | ++++ | 94 | ++ | 97 | + | |
| 95 | + | 96 | + | 96 | + | 100 | − | |
| 95 | + | 95 | + | 100 | − | 100 | − | |
Notes:
Control antibacterial levofloxacin 3.25 μg;
transmittance of treated spores at λ=405 nm.
Figure 1(A) Scanning electron microscopy of normal Candida albicans cells and (B) treated C. albicans cells.
Figure 2(A) Scanning electron microscopy of normal Staphylococcus aureus cells and (B) treated S. aureus cells.
Figure 3(A) Scanning electron microscopy of normal Escherichia coli cells and (B) treated E. coli cells.